The dysregulation of H19 in thyroid cancer is subject of controversy since the down-regulation was reported in FTC [126] and PTC [127], while the overexpression is reported in PTC, ATC [117] and PTC/PTC stem cells (PTCSCs) [118]. Here, H19 is linked to thyroid gland carcinoma.